<DOC>
	<DOCNO>NCT01165060</DOCNO>
	<brief_summary>X-linked adrenoleukodystrophy ( X-ALD ) inherit metabolic disorder characterise accumulation long chain fatty acid ( VLCFA ) plasma tissue . Presumably accumulation responsible tissue damage . The disease cause severe demyelinisation central nervous system usually cause death childhood progressive ambulatory problem adult cause progressive myelopathy . For latter category patient curative treatment currently available . Recent investigation human fibroblast mice identify bezafibrate agent might reduce VLCFA patient X-ALD . Objective study : The trial design open-label pilot study . The main goal investigate bezafibrate reduce VLCFA vivo patient X-ALD . If indeed biochemical effect , large follow-up study initiate clinical outcome parameter . Study design : 10 men X-ALD use bezafibrate period 6 month ( combination low fat diet ) . On 6 different time point participant undergo venipuncture detect possible side effect determine biochemical outcome parameter . Study population : Adult men X-linked adrenoleukodystrophy . Intervention ( applicable ) : Bezafibrate . Primary study parameters/outcome study : The primary outcome parameter cholesterol level ( total- , LDL , HDL ) level triglyceride plasma , VLCFA level plasma , leukocytes erythrocyte also C26:0-lyso-PC bloodspots . Secondary study parameters/outcome study ( applicable ) : Secondary outcome parameter side-effects ( subjective abnormality safety lab ) .</brief_summary>
	<brief_title>The Effect Bezafibrate Level Very Long Chain Fatty Acids ( VLCFA ) X-linked Adrenoleukodystrophy ( X-ALD )</brief_title>
	<detailed_description />
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<mesh_term>Bezafibrate</mesh_term>
	<criteria>age 18 year older capable give informed consent capable visit hospital followup visit contraindication use bezafibrate , e.g . kidney and/or liver disease . confirm XALD , AMN phenotype ( confirm VLCFA analysis analysis ABCD1 gene ) use medication lower cholesterol and/or triglyceride ( e.g . statin ) liver disease increase serum CK 3 time baseline level treatment Lorenzo 's oil 8 week precede trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>X-ALD</keyword>
	<keyword>AMN</keyword>
	<keyword>adrenomyeloneuropathy phenotype</keyword>
</DOC>